MBA

Carol MacKinlay Joins Tech CU’s Board of Directors

Retrieved on: 
Thursday, February 29, 2024

SAN JOSE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, Tech CU (Technology Credit Union) announced the appointment of Carol MacKinlay to its Board of Directors.

Key Points: 
  • SAN JOSE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, Tech CU (Technology Credit Union) announced the appointment of Carol MacKinlay to its Board of Directors.
  • With over 30 years of experience in executive leadership roles, Carol brings a wealth of expertise in human resources, corporate governance, and fostering organizational excellence.
  • "We are thrilled to welcome Carol to our Board of Directors," said Todd Harris, the CEO at Tech CU.
  • In addition to serving on the Tech CU board, Carol serves on the boards of Exodus and Nitro Workforce Solutions.

Opthea Reports Half-Year Financial Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024

MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced financial results for the six months ended December 31, 2023 and highlighted recent corporate and clinical updates.

Key Points: 
  • We recently announced the completion of enrollment in our first pivotal Phase 3 trial (COAST), in combination with EYLEA® (aflibercept),” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea.
  • Peter Lang, Chief Financial Officer of Opthea, added, “We are excited about Opthea’s progress.
  • Top-line Phase 3 results from the COAST and ShORe trials expected by mid-CY 2025.
  • In August 2023, Opthea successfully completed a private placement and rights equity offering raising A$90 million (US$58 million) in Australia.

Altus Group Nominates Jim Hannon and Will Brennan to its Board of Directors

Retrieved on: 
Wednesday, February 28, 2024

“Our strategic growth plan includes expanding Altus Group’s asset performance and risk management solutions to help clients drive superior performance through advanced analytics.

Key Points: 
  • “Our strategic growth plan includes expanding Altus Group’s asset performance and risk management solutions to help clients drive superior performance through advanced analytics.
  • Their addition to the Board is an important step in our ongoing board refreshment process.”
    Will Brennan is the Managing Partner of Long Path Partners, an investment firm that he founded in 2018, and a long-standing shareholder of Altus Group.
  • He brings a unique investor perspective to the Board with a deep understanding of Altus Group’s operations and market opportunity.
  • Both directors have made lasting contributions to Altus Group’s corporate governance initiatives and continual efforts to drive shareholder value.

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Retrieved on: 
Wednesday, February 28, 2024

SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced the appointment of Britton Russell as Chief Financial Officer.

Key Points: 
  • SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced the appointment of Britton Russell as Chief Financial Officer.
  • Mr. Russell brings a wealth of experience working with both emerging growth companies and large multinational organizations to support long-term growth objectives.
  • “Britton brings a unique experience of scaling early stage, innovative life science organizations through significant periods of growth and development,” said Andy Scharenberg, M.D., Co-Founder and Chief Executive Officer of Umoja.
  • I am excited to join the team at this important stage of growth.”
    Mr. Russell joins Umoja after previously serving as Chief Financial Officer at Parse Biosciences, a single-cell sequencing company, and Genapsys, a DNA sequencing company.

Perdue Farms Welcomes Todd Tillemans as New Chief Commercial Officer to Drive Growth and Innovation

Retrieved on: 
Tuesday, February 27, 2024

Salisbury, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Perdue Farms, a fourth-generation, family-owned U.S. food and agricultural products company, today announced Todd Tillemans as its new Chief Commercial Officer (CCO).

Key Points: 
  • Salisbury, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Perdue Farms, a fourth-generation, family-owned U.S. food and agricultural products company, today announced Todd Tillemans as its new Chief Commercial Officer (CCO).
  • Prior to Hershey, he led multiple businesses across global markets for Unilever and, before that, held positions at General Mills.
  • He is an alumnus of the University of Minnesota and received his MBA from the University of Chicago Booth School of Business.
  • “I’m thrilled to join the Perdue Farms team and I look forward to all that we can accomplish in partnership with our customers, on behalf of our consumers,” said Tillemans.

Peapack Private Hires Ron Bezoza as Senior Managing Director - Managing Principal, Head of Sales and Relationship Management

Retrieved on: 
Tuesday, February 27, 2024

BEDMINSTER, NJ, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market:  PGC) announces the appointment of Ron Bezoza as Senior Managing Director - Managing Principal, Head of Sales and Relationship Management at Peapack Private, a division of Peapack-Gladstone Bank.

Key Points: 
  • BEDMINSTER, NJ, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market:  PGC) announces the appointment of Ron Bezoza as Senior Managing Director - Managing Principal, Head of Sales and Relationship Management at Peapack Private, a division of Peapack-Gladstone Bank.
  • Mr. Bezoza is also responsible for expanding Peapack Private’s footprint through recruiting and business development.
  • At Morgan Stanley, Ron was Managing Director, Head of Managed Solutions Group and Business Development for the Solutions & Multi-Asset Group at Morgan Stanley in New York, NY.
  • During his 11-year tenure at Goldman Sachs, Ron served as Managing Director and Global Head of Private Wealth Management Equity Solutions Group and played a pivotal role in shaping the mass affluent and high-net-worth client segments.

Local Pharmacies on the Brink, New Survey Reveals

Retrieved on: 
Tuesday, February 27, 2024

The rule is intended to give pharmacies and patients more transparency on drug pricing.

Key Points: 
  • The rule is intended to give pharmacies and patients more transparency on drug pricing.
  • According to the new NCPA survey, 32 percent of all respondents say they are considering closing their doors in 2024 because of the cash crunch.
  • Increased vertical and horizontal consolidation of PBMs and health plans has caused severe inequities to pharmacies and Medicare Part D beneficiaries alike.
  • Community pharmacies are rooted in the communities where they are located and are among America’s most accessible health care providers.

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Retrieved on: 
Monday, February 26, 2024

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase.
  • This deal supersedes the prior exclusive license on the EvoT4™ DNA ligase.
  • We are excited to collaborate again with Roche on this novel, dsDNA ligase.
  • Compared to wild-type enzyme, the newly engineered dsDNA ligase is developed to higher ligation efficiency in shorter reaction times and higher library yields and complexity, with minimal substrate sequence bias.

Guggenheim Securities Hires Michael Cannon to Expand Energy Investment Banking Practice

Retrieved on: 
Monday, February 26, 2024

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Cannon will join the firm as a Senior Managing Director in the firm’s Energy investment banking practice.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Cannon will join the firm as a Senior Managing Director in the firm’s Energy investment banking practice.
  • Mr. Cannon joins Guggenheim with approximately four decades of investment banking experience, having recently served as Co-Head of Americas Energy Investment Banking at Bank of America.
  • “We are excited to welcome Michael to Guggenheim,” said Mark Van Lith, CEO of Guggenheim Securities.
  • We look forward to Michael’s contributions to the continued development of our energy business.”
    Mr. Cannon holds a B.S.